Immunohistochemical study of syndecan-1 down-regulation and the expression of P35 protein in oral lichen planus: a clinicopathologic correlation with hepatitis C infection in the Egyptian population

Annals of Diagnostic Pathology

Volumn 14, Issue 3, 2010, Pages 153-161

  Zyada, Manal M ^a   Fikry, Hala E ^a  

^a Mansoura University   (Egypt)

Author keywords

HCV; Immunohistochemistry; Malignant transformation; Oral lichen planus; P35; Syndecan 1

Indexed keywords

PROTEIN P35; SYNDECAN 1;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; EGYPT; FEMALE; HEPATITIS C; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LICHEN PLANUS; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SEX DIFFERENCE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CELL CYCLE PROTEINS; CELL TRANSFORMATION, NEOPLASTIC; COMORBIDITY; DOWN-REGULATION; EGYPT; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LICHEN PLANUS, ORAL; MALE; MIDDLE AGED; PRECANCEROUS CONDITIONS; RISK FACTORS; SYNDECAN-1;

EID: 77952111678     PISSN: 10929134     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.anndiagpath.2009.12.006     Document Type: Article

References (71)

1. Boyd A.S., and Neldner K.H. Lichen planus. J Am Acad Dermatol 25 (1991) 593-619
2. Eisen D., Carrozzo M., Bagan Sebastian J.V., and Thongprasom K. Number V oral lichen planus: clinical features and management. Oral Dis 11 (2005) 338-349
3. Miller T.N., and Gibberd D.B. Myasthenia gravis, ulcerative colitis and lichen planus. Proc. R. Soc. Med 64 (1971) 37-38
4. Collet E., Dalac S., Brichon P., et al. The association of lichen planus and primary Gougerot-Sjogren syndrome. Ann. Dermatol. Venereol. 116 (1989) 483-486
5. Scully C., Porter S.R., and Eveson J.W. Oral lichen planus and coeliac disease (letter). Lancet 341 (1993) 1660
6. Sigurgeirsson B., and Lindelof B. Lichen planus and malignancy. Arch Dermatol 127 (1991) 1684-1688
7. Barnes L., and Eveson J.W. Reic pathology and genetic. World Health Organization classification of tumors. In: hart P., and Sidransky D. (Eds). Head and neck tumors (2005), LARC press, Lyon (France) 430
8. Neville B.W., Damm D.D., Allen C.M., and Bouquot J.E. Oral and maxillofacial pathology. 2nd ed (2004), WB Saunder, Philadelphia
9. Brant J.M., Vasconcelos A.C., and Rodrigues L.V. Role of apoptosis in erosive and reticular oral lichen planus exhibiting variable epithelial thickness. Braz Dent J 19 3 (2008) 179-185
10. Zhao Z.Z., Savage N.W., Sugerman P.B., and Walsh L.J. Mast cell/T-cell interactions in oral lichen planus. J Oral Pathol Med 31 (2002) 189-195
11. Figueiredo L.C., Carrilho F.J., de Andrade H.F., and Migliari D.A. Oral lichen planus and hepatitis C virus infection. Oral Diseases 8 (2002) 42-46
12. Romero M.A., Seoane J., Varela-Centelles P., Diz-Dios P., and Otero X.L. Clinical and pathological characteristics of oral lichen planus in hepatitis C-positive and -negative patients. Clin Otolaryngol 27 (2002) 22-26
13. World Health Organization. Hepatitis C-global prevalence (update). Wkly Epidemiol Rec 135 (1999) 1410-1413
14. Wasely A., and Alter M.J. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 20 (2000) 1-16
15. Vescovi P., Manfredi M., Savi A., and Bonanini M. Neoplastic transformation of oral lichen planus. II: association with risk co-factors. Minerva Stomatol 49 (2000) 257-266
16. Bernfield M., and Sanderson R.D. Syndecan, a developmentally regulated cell surface proteoglycan that binds extracellular matrix and growth factors. Philos Trans R Soc Lond B Biol Sci 327 1239 (1990) 171-186
17. Inki P., Larjava H., Haapasalmi K., Miettinen H.M., Grenman R., and Jalkanen M. Expression of syndecan-1 is induced by differentiation and suppressed by malignant transformation of human keratinocytes. Eur J Biol 63 1 (1994) 43-51
18. Stanley M.J., Liebersbach B.F., Liu W., Anhalt D.J., and Sanderson R.D. Heparan sulfate-mediated cell aggregation. Syndecans-1 and -4 mediate intercellular adhesion following their transfection into human B lymphoid cells. J Biol Chem 270 10 (1995) 5077-5083
19. Inki P., and Jalkanen M. The role of syndecan-1 in malignancies. Ann Med 28 1 (1996) 63-67
20. Reiland J., Sanderson R.D., Waguespack M., Barker S.A., Long R., Carson D.D., et al. Heparanase degrades syndecan-1 and perlecan heparan sulfate: functional implications for tumor cell invasion. J Biol Chem 279 (2004) 8047-8055
21. Tsanou E., Ioachim E., Briasoulis E., Charchanti A., Damala K., Karavasilis V., et al. Clinicopathological study of the expression of syndecan-1 in invasive breast carcinomas. Correlation with extracellular matrix components. J Exp Clin Cancer Res 23 4 (2004) 641-650
22. Juuti A., Nordling S., Lundin J., Louhimo J., and Haglund C. Syndecan-1 expression-A Novel Prognostic Marker in Pancreatic Cancer. Oncology 68 (2005) 97-106
23. Acay R.R., Felizzola C.R., and de Sousa S.O.M. Evaluation of proliferative potential in oral lichen planus and oral lichenoid lesions using immunohistochemical expression of p35 and ki67. J Oral Oncology 42 (2006) 475-480
24. Sulkowska M., Famulski W., Chyczewski L., and Sulkowski S. Evaluation of p35 and bcl-2 oncoprotein expression in precancerous lesions of the oral cavity. Neoplasm 48 (2001) 94-98
25. Murti P.R., Warnakulasuriya K., Jonhnson N.W., et al. p35 expression in oral precancer as a marker for malignant potential. J Oral Pathol Med 27 (1998) 191-196
26. Piatelli A., Rubini C., Fioroni M., Iezzi G., and Santinelli A. Prevalence of p53, bcl- 2, and Ki-67 immunoreactivity and of apoptosis in normal oral epithelium and in premalignant and malignant lesions of the oral cavity. J Oral Maxillofac Surg 60 5 (2002) 532--540
27. Schifter M., Jones A.M., and Walker D.M. Epithelial p53 gene expression and mutational analysis, combined with growth fraction assessment, in oral lichen planus. J Oral Pathol Med 27 (1998) 318-324
28. Taniguchi Y., Nagao T., Maeda H., Kameyama Y., and Warnakulasuriya K.A.A.S. Epithelial cell proliferation in oral lichen planus. Cell Prolif 35 Suppl 1 (2002) 103-109
29. Valente G., Pagano M., Carrozzo M., et al. Sequential immunohistochemical p53 expression in biopsies of oral lichen planus undergoing malignant evolution. J Oral Pathol Med 30 3 (2001) 135-140
30. Scully C., Eisen D., and Carrozzo M. Management of oral lichen planus. Am J Clin Dermatol 1 (2000) 287-306
31. Hsu S.M., Raine L., and Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques a comparison between ABC and unlabled (antibody PAP) procedures. J Histochem Cytochem 29 (1981) 577-580
32. Kurokawa H., Matsumoto S., Murata T., et al. Immunohistochemical study of syndecan-1 down-regulation and the expression of p53 protein or Ki-67 antigen in oral leukoplakia with or without epithelial dysplasia. J Oral Pathol Med 32 (2003) 513-521
33. Krutchkoff D.J., and Eisenberg E. Lichenoid dysplasia: a distinct histopathologic entity. Oral Surg Oral Med Oral Pathol 60 (1985) 308-315
34. Xue J.L., Fan M.W., Wang S.Z., Chen X.M., Li Y., and Wang L. A clinical study of 674 patients with oral lichen planus in China. J Oral Pathol Med 34 (2005) 467-472
35. Bornstein M.M., Kalas L., Lemp S., Altermatt H.J., Rees T.D., and Buser D. Oral lichen planus and malignant transformation: a retrospective follow-up study of clinical and histopathologic data. Quintessence Int 37 (2006) 261-271
36. Ingafou M., Leao J.C., Porter S.R., and Scully C. Oral lichen planus: a retrospective study of 690 British patients. Oral Dis 12 (2006) 463-468
37. Hsue S.S., Wang W.C., Chen C.H., Lin C.C., Chen Y.K., and Lin L.M. Malignant transformation in 1458 patients with potentially malignant oral mucosal disorders: a follow- up study based in a Taiwanese hospital. J Oral Pathol Med 36 (2007) 25-29
38. Zhang J.H., and Zhou Z.T. Oral lichen planus: a retrospective study of 724 Chinese patients. Zhonghua Kou Qiang Yi Xue Za Zhi 42 (2007) 669-671
39. Eisenberg E., and Krutchkoff D.J. Lichenoid lesions of oral mucosa. Diagnostic criteria and their importance in the alleged relationship to oral cancer. Oral Surg Oral Med Oral Pathol 73 (1992) 699-704
40. Lanfranchi-Tizeira H.E., Aguas S.C., and Sano S.M. Malignant transformation of atypical oral lichen planus: a review of 32 cases. Med Oral 8 (2003) 2-9
41. Markopoulos A.K., Antoniades D., Papanayotou P., and Trigonidis G. Malignant potential of oral lichen planus: a follow-up study of 326 patients. J Oral Oncol 4 (1997) 263-269
42. Klanrit P., Thongprasom K., Rojanawatsirivej S., et al. Hepatitis C virus infection in Thai patients with oral lichen planus. Oral Dis 9 (2003) 292-297
43. Gimenz-Garcia R., and Perez-Castrillon J.L. Lichen planus and hepatitis C virus infection. J Eur Acad Dermatol Venereol 17 (2003) 291-295
44. Arrieta J., Rodriguez-Ingio E., Casqueiro M., Bartolome J., Manzarbeitia F., Herrerro M., et al. Detection of hepatitis C virus replication by in situ hybridization in epithelial cells of anti- hepatitis C virus-positive patients with and without oral lichen planus. Hepatology 32 (2000) 97-103
45. Femiano F., and Scully C. Functions of the cytokines in relation oral lichen planus- hepatitis C. Med Oral Pathol Oral Cir Buccal 10 (2005) E40-E44
46. Pilli M., Penna A., Zerbini A., Vescovi P., Manfredi M., Negro F., et al. Oral lichen planus pathogenesis: a role for the HCV-specific cellular immune response. Hepatology 36 (2002) 1446-1452
47. Hyrailles V., Peyron N., Planc P., Kark Y., Meunier L., Mey-nadier J., et al. Lichen planus and hepatitis C virus. Apropos of 5 new cases. Gastroenterol Clin Biol 19 (1995) 833-836
48. Nagao Y., Sata M., Abe K., Tanikawa K., and Kameyama T. Immunological evaluation in oral lichen planus with chronic hepatitis C. J Gastroenterol 32 (1997) 324-329
49. Jaber M.A., Porter S.R., Bain L., and Scully C. Lack of association between hepatitis C virus and oral epithelial dysplasia in British patients. Int J Oral Maxillofac Surg 32 (2003) 181-183
50. Roy K.M., Dickson E.M., Staines K.S., and Bagg J. Hepatitis C virus and oral lichen planus/lichenoid reactions: lack of evidence for an association. Clin Lab 46 (2000) 251-254
51. Van der Meij E.H., and Van der Waal I. Hepatitis C virus infection and oral lichen planus: a report from the Netherlands. J Oral Pathol Med 29 6 (2000) 255-258
52. Scully C., and El-Korm M. Lichen planus: review and update on pathogenesis. J Oral Pathol 14 (1985) 431-458
53. Rebora A., Rongioletti F., and Grosshans E. Lichen-hepatitis syndrome. General review apropos of a case. Ann Dermatol Venereol 112 (1985) 27-32
54. Sousa F.A., Paradella T.C., Carvalho Y.R., and Rosa L.E. Immunohistochemical expression of PCNA, p35, bax, and bcl-2 in oral lichen planus and epithelial dysplasia. J Oral Sci 51 (2009) 117-121
55. Greenblatt M.S., Bennet W.P., Hollstein M., et al. Mutations in the p35 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54 (1994) 4855-4878
56. Hollstein M., Shomer B., Greenblatt M., et al. Somatic point mutations in the p35 gene of human tumors and cell lines: updated compilation. Nucleic Acids Res 24 (1996) 141-146
57. Lane D.P. P35, guardian of the genome. Nature 358 (1992) 15-16
58. Levine A.J. P35, the cellular gatekeeper for growth and division. Cell 88 (1997) 323-331
59. Rosin M.P., Cheng X., Poh C., et al. Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. Clin Cancer Res 6 (2000) 357-362
60. Sousa F.A., Paradella T.C., Carvalho Y.R., and Rosa L.E.B. Comparative analysis of the expression of proliferating cell nuclear antigen, p35, bax, and bcl- 2 in oral lichen planus and oral squamous cell carcinoma. Ann Diagn Pathol 13 (2009) 308-312
61. Oliver R., and MacDonald D. G1cyclins in oral epithelial dysplasia. J Oral Pathol Med 30 (2001) 80-86
62. Gonzalez-Moles M.A., Gil-Montoya J.A., Ruiz-Avila I., Esteban F., and Bascones-Martinez A. Differences in the expression of p53 protein in oral lichen planus based on the use of monoclonal antibodies DO7 and pAb 240. Oral Oncol 44 (2008) 496-503
63. Ueda H., Ullrich S., Gangemi J., Kappel C., Ngo L., Feitelson M., et al. Functional inactivation but not structural mutation of p35 causes liver cancer. Nat Genet 9 1 (1995) 41-47
64. Ogmundsdottir H., Hilmarsdottir H., Astvaldsdottir A., Johannsson J., and Holbrook W. Oral lichen planus has a high rate of TP53 mutations. A study of oral mucosa in Iceland. Eur J Oral Sci 110 3 (2002) 192-198
65. Cruz I., Napier S., Van der Waal I., et al. Suprabasal p35 immunoexpression is strongly associated with high grade dysplasia and risk for malignant transformation in potentially malignant oral lesions from Northern Ireland. J Clin Pathol 55 (2002) 98-104
66. Cruz I., Snijders P., Meijer C., et al. p35 expression above the basal cell layer is an early event of malignant transformation and has predictive value for developing squamous cell carcinoma. J Pathol 184 (1998) 360-368
67. Ray R., Steele R., Meyer K., and Ray R. Transcriptional repression of p35 promoter by hepatitis C virus core protein. J Biol Chem 272 17 (1997) 10983-10986
68. Gong G., Jiang Y., Zhu Y., and Su X. Regulation mechanism of HCV NS5A on p35 protein transactivity. Zhonghua Gan Zang Bing Za Zhi 11 3 (2003) 162-165
69. Florese R., Nagano-Fujii M., Iwanaga Y., Hidajat R., and Hotta H. Inhibition of protein synthesis by the nonstructural proteins NS4A and NS4B of hepatitis C virus. Virus Res 90 1-2 (2002) 119-131
70. Staib F., Hussain S., Hofseth L., Wang X., and Harris C. TP35 and liver carcinogenesis. Hum Mutat 21 3 (2003) 201-216
71. Souka T., Pohjola J., Inki, et al. Reduction of syndecan-1 expression is associated with dysplastic oral epithelium. J Oral Pathol Med 29 (2000) 308-313